報價延遲最少15分鐘:2025/04/12 05:22 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
24.12 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.98/-3.44
|
|
企業價值
1.53B
|
| 資產負債 |
|
每股賬面淨值
12.87
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
47.07M
|
|
每股收益
0.72
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/04/12 05:22 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4. |